Press Releases

  • McKesson Ventures Invests as Clinical Ink Debuts Lunexis™ ePRO+ Solution

    Clinical Ink, a global clinical trial technology company, today announced an investment from McKesson Ventures alongside its significantly enhanced electronic patient reported outcome (ePRO) module. Lunexis™ ePRO+ is part of a unified technology platform that streamlines implementation processes and allows patients and sites to choose how they want to participate in the study — smartphone, tablet, or web. Lunexis ePRO+ allows sites and patients to have unprecedented flexibility to choose the technology option that makes the most sense for them.

    Dec 2, 2020

  • Independent Discovery Validates Noxopharm’s DARRT Cancer Therapy

    Australian clinical-stage drug development company, Noxopharm (ASX: NOX), is pleased to announce that a discovery by Weill Cornell Medical College in New York, recently published in the prestigious scientific journal, Nature Immunology, significantly validates the novel DARRT anti-cancer treatment of its drug candidate, Veyonda®, in producing radiation-induced abscopal responses, regarded by many as the ultimate form of treatment for metastatic cancer

    Dec 2, 2020

  • Cerner and Elligo to Make Clinical Trials Accessible for Health Systems of All Sizes

    Cerner Corporation (NASDAQ: CERN), a global health care technology company, today announced an investment in Elligo Health Research, a leading integrated research organization that enables clinical trials with nationwide community-based health care practices.

    Dec 7, 2020

  • APIS Assay Technologies Ltd. and Moffitt Cancer Center sign Master Collaboration Agreement on TROLL Biomarker assessment

    APIS Assay Technologies has announced a master collaboration agreement with Moffitt Cancer Centre to characterise the suitability of TROLL-2 and TROLL-3 as predictive biomarkers of cancer progression with the goal to assess the role of TROLLs as markers of response to chemotherapy. The research collaboration will aim to determine the feasibility of lncRNAs as a diagnostic tool for the prediction of efficacy of treatment pathways and prognosis of treatment outcome in chemoresistant TNBCs and further analysing NSCLC and melanoma as potential diagnostic targets for the TROLL Biomarkers.

    Dec 9, 2020

  • Alpha Solway honours top doctor with new ‘People’s Choice’ award

    Scottish kidney specialist named winner at Scottish Health Awards for crucial work during coronavirus outbreak.

    Dec 9, 2020

  • Solis Mammography Adopts iCAD’s ProFound AI Platform Powered by Panorama with Short-Term Breast Cancer Risk Assessment Solution

    iCAD ProFound AI for 3D Mammography and ProFound AI Risk will be deployed to 100 percent of Solis Mammography’s installed base, a majority of which are Hologic systems. The agreement is not exclusive. The agreement underscores promise of shifting mammography from age-based screening paradigm to a risk-adjusted precision screening paradigm personalized for every woman. ProFound AI, which aids in the detection of breast cancer in 3D mammography, or digital breast tomosynthesis (DBT), became the first software of its kind to be FDA-cleared in December 2018. The technology rapidly and accurately analyzes each DBT image, or slice, and provides radiologists with key information, such as Certainty of Finding lesion and Case Scores, which assists in clinical decision-making and improving reading efficiency. *Delivers clinically proven improvements in sensitivity, specificity, time-savings and recall rates. This leads to earlier breast cancer detection and reduced rate of false positive *ProFound AI Risk is the only commercially available risk assessment solution to provide a short term vs. long term risk of developing breast cancer based solely on a screening mammogram. *ProFound AI for DBT is proven to curtail workflow challenges substantially by reducing radiologists’ reading time by 52.7%, thereby reducing by half the amount of time it takes radiologists to read 3D mammography datasets.

    Dec 10, 2020

  • Medovate announces new agreement with Mercury Medical® securing 100% distributor coverage for SAFIRA™ in the USA

    https://news.lifesciencenewswire.com/newsroom/medovate-announces-new-agreement-with-mercury-medical-securing-100-distributor-coverage-for-safira-in-the-usa

    Dec 14, 2020

  • ENPICOM and MiLaboratories join forces to power better Repertoire Sequencing data management and analysis workflows

    ENPICOM BV, an innovative bioinformatics software engineering company, has announced a strategic partnership with MiLaboratories LLC, a technology leader in profiling the mammalian adaptive immune system, to enhance Repertoire Sequencing data management and analysis workflows. The collaboration provides a software solution within a single platform, by combining MiLaboratories's MiXCR and ENPICOM’s cloud-based IGX Platform, allows users to choose their preferred profiling solution, leverage its intuitive user interface and unique data management capabilities.

    Dec 14, 2020

  • New Study Confirms VisualDx’s AI Improves Diagnostic Accuracy at the Point of Care

    A new study reveals that VisualDx's artificial intelligence solution identifies skin conditions with 68% accuracy across all skin types.

    Dec 8, 2020

  • Clinical Ink Celebrates 5 Years of Decentralized Trial Experience

    Clinical Ink, a global clinical trial technology company, today announced five years of providing clients with decentralized and hybrid trial solutions. To demonstrate our continued commitment to industry leadership and the movement toward more patient-centric clinical trials, Clinical Ink has joined the Decentralized Trials & Research Alliance (DTRA), which enables collaboration of stakeholders to accelerate the adoption of patient-focused, decentralized clinical trials and research within life sciences and healthcare through education and research.

    Dec 9, 2020

  • THREAD Joins Leading Life Sciences Organizations to Advance Decentralized Clinical Research

    THREAD, an innovative technology and service provider that enables decentralized clinical research, joins a formidable alliance of 50 life sciences and healthcare organizations to accelerate the broad adoption of patient-focused decentralized clinical trials and research.

    Dec 9, 2020

  • Research reveals portable digital chest drainage systems could help minimise spread of COVID-19

    Pioneering research conducted by a team of thoracic consultants from Guy’s and St Thomas’ NHS Foundation Trust – home to one of the largest lung cancer practices in the UK – has revealed digital chest drains generate and distribute less aerosol generated particles compared to traditional water seal systems. At the start of the coronavirus pandemic there was limited evidence about the spread of COVID-19 via chest drains which led to uncertainty within the thoracic community about the best medical device to use. Researchers reviewed three different types of chest drainage systems – single chamber, 3 compartment wet-dry suction, and digital drainage system. Results showed that the 3-compartment wet-dry suction system and the digital drainage system did not generate any identifiable aerosolised particles at any of the air leak or drain output volumes considered. Medela’s Thopaz+, a digital chest drainage, and monitoring system can effectively retain pathogen-sized particles and prevent them from subsequently exiting to the environment via the exhaust. Fully supported by clinical evidence from the National Institute for Health and Care Excellence (NICE), Thopax+ is proven to improve outcomes, ensuring a safe and continuous drainage independent of a wall vacuum to provide safer patient care while minimising the risk of cross-contamination.

    Dec 9, 2020

  • CluePoints Opens New AsiaPac Office in Tokyo

    CluePoints, the premier provider of Central Statistical Monitoring, Risk-Based Quality Management and Data Quality Oversight Software for clinical trials, today announced further expansion in Japan with the opening of a new office in Tokyo. Dedicated to serving their Japanese clients, the new office builds on CluePoints’ presence in the region, as demand for modern analytical software and services enabling proactive and exhaustive identification of clinical study quality issues continues to grow. The new location, along with a team located in Osaka, will strengthen CluePoints’ growing reputation within Japan and bring it closer to its Asia-Pacific region customers.

    Dec 7, 2020

  • PolyActiva appoints Tracy Valorie, ophthalmic industry expert and former Bausch + Lomb executive, to its Board of Directors

    PolyActiva Pty Ltd, a clinical-stage ophthalmology biopharmaceutical company, announced the appointment of highly experienced ophthalmic industry expert, Tracy Valorie, as a new member to the company’s Board of Directors.

    Nov 1, 2020

  • AstraZeneca Partners with CCT to Conduct COVID-19 Vaccine Clinical Trials in Arizona

    Together with local healthcare providers, CCT will facilitate clinical trials for the AZD1222 COVID-19 VACCINE, an investigational vaccine for the prevention of COVID-19. CCT is recruiting eligible study participants who are 18 years of age or older, not pregnant, in good general health and have not been previously diagnosed with COVID-19.

    Nov 11, 2020

  • U.S. Department of Veterans Affairs Begins National Rollout of WCG’s IRBNet Research Oversight and Reporting Software as a Service (SaaS) Solution

    Software will enhance research oversight, improve transparency and expedite veterans’ access to clinical trials for more than 100 VA medical centers that have research programs

    Nov 8, 2020

  • Rho Federal Systems Division, Inc. Awarded Statistical and Data Coordinating Center Contract in BARDA Medical Countermeasures Clinical Studies Network

    Rho Federal Systems Division, Inc. Awarded Statistical and Data Coordinating Center Contract in BARDA Medical Countermeasures Clinical Studies Network CRO will serve to standardize data collection, management, and analysis across BARDA-supported network studies. Research Triangle Park, NC – November 9, 2020 – Rho, a full-service contract research organization (CRO) that helps pharmaceutical and biotechnology companies bring their products to market through high-quality clinical research services, announces the Rho Federal Systems Division, Inc. (RhoFED) was awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services to manage a Statistical and Data Coordinating Center (SDCC) for BARDA’s Medical Countermeasures Clinical Studies Network. Under the contract, RhoFED will be responsible for standardizing data collection, management, and analysis across BARDA-supported network studies.

    Nov 8, 2020

  • Shimmer Research Receives CE Certification for its Verisense™ Inertial Measurement Unit (IMU) Sensor for Clinical Trials

    Shimmer’s wearable sensor is now recognized as a medical device in Europe, capable of providing continuous, medical-grade measurements of a person’s activity.

    Nov 9, 2020

  • SCORR Releases 2020 Report on Health Science Company Marketing Trends

    SCORR Marketing, a global health science marketing and communications firm, has released its eighth annual survey report, Marketing Trends in Health Science Services Companies. The report is free and features data that health science executives and marketers can use to understand how companies are approaching marketing in the midst of the COVID-19 pandemic. The report provides valuable insights that can guide strategic planning, budgeting, and tactics in the year ahead.

    Nov 9, 2020

  • GT Medical Technologies Announces First Patient Treated in Registry Trial of GammaTile Therapy for Brain Tumors

    GT Medical Technologies, Inc., a company dedicated to improving the lives of patients with brain tumors, today announced the first patient has been enrolled into its registry trial of GammaTile®, a FDA-cleared, Surgically Targeted Radiation Therapy (STaRT) for newly diagnosed malignant and recurrent brain tumors. The study will evaluate the safety and effectiveness of GammaTile Therapy in a real-world setting in up to 50 brain tumor centers across the United States.

    Nov 9, 2020